Quantcast

Latest Fluticasone/salmeterol Stories

2014-09-19 08:26:05

DALLAS, September 19, 2014 /PRNewswire/ -- RnRMarketResearch.com adds asthma drugs market research reports titled "Asthma - Japan Drug Forecast and Market Analysis to 2023", "Asthma - US Drug Forecast and Market Analysis to 2023" and "Asthma - 5EU Drug Forecast and Market Analysis to 2023" to its online library. According to Asthma - 5EU Drug Forecast and Market Analysis to 2023...

2014-09-16 08:29:41

Clinical Trials Mark Important Milestone in Development of Two Highly Complex Products PITTSBURGH, Sept. 16, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), one of the world's leading global pharmaceutical companies, today announced it is initiating Phase III clinical trials for its generic version of GlaxoSmithKline's Advair Diskus® and its insulin analog to Sanofi's Lantus®. http://photos.prnewswire.com/prnvar/20140423/77793 In October 2014, Mylan will commence a Phase III...

2014-09-11 04:21:18

OXFORD, England, September 11, 2014 /PRNewswire/ -- Successful Completion of Biomedical Catalyst Programme Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, announces that it has confirmed the potential of its Multi-component Particle(TM) (MCP(TM)) Technology for creating novel inhaled, dual and triple fixed dose combination (FDC) therapies for respiratory diseases. The Company...

2014-09-02 04:21:24

QXFORD, England, September 2, 2014 /PRNewswire/ -- Triggers milestone payment from Mylan Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, announces that its Marketing Authorisation Application (MAA) for PSX1001 has been validated and is being assessed under the Decentralised Procedure (DCP), in which the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) is...

2014-07-24 12:27:40

While Expressing Concerns about Reimbursement, EU5 Payers Look Favorably on Identifying Anti-IL5 Therapy-Responsive Patients, According to Findings from Decision Resources Group BURLINGTON, Mass., July 24, 2014 /PRNewswire/ -- Decision Resources Group finds that, for the treatment of asthma, pulmonologists in the EU5 countries (France, Germany, Italy, Spain and the United Kingdom) hold a generally positive view of the first once-daily long-acting beta2 agonist/inhaled corticosteroid...

2014-06-10 23:03:31

The GlaxoSmithKline settlement involves the District of Columbia and 44 states over the marketing of Advair, Paxil, and Wellbutrin. Port Washington, NY (PRWEB) June 10, 2014 Parker Waichman LLP, a national law firm representing the victims of defective drugs is commenting on a recent settlement by drug maker, GlaxoSmithKline, over allegations involving the way in which Advair, Paxil, and Wellbutrin were marketed and how the drugs were promoted for off-label uses. According to a The...

2014-06-03 12:37:54

LONDON, June 3, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Asthma and COPD Therapies: World Market 2013-2023http://www.reportbuyer.com/pharma_healthcare/diseases/asthma/asthma_copd_therapies.html Report DetailsNew study reveals sales potential of this large, expanding marketSee what the future holds for asthma and COPD therapies. Visiongain's report gives you drug revenue predictions to 2023. You find data, trends, opportunities and commercial...

2014-05-19 20:21:48

LONDON, May 19, 2014 /PRNewswire/ -- GlaxoSmithKline plc (LSE: GSK) today presented data at the American Thoracic Society (ATS) from a late-stage clinical study. In this study the safety and efficacy of the addition of a long-acting muscarinic antagonist (also known as an anticholinergic), umeclidinium 'UMEC' 62.5mcg (Incruse(TM)( )Ellipta(®)) and UMEC 125mcg, to the inhaled corticosteroid and long-acting beta2 agonist combination medicine, fluticasone proprionate and salmeterol 'FSC...

2014-05-15 04:22:31

OXFORD, England, May 15, 2014 /PRNewswire/ -- First full presentation of data from randomised clinical study of glycopyrronium bromide made using Prosonix' novel particle-engineering technology Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, announces that it will present results from its Phase 2 clinical study with PSX1002 in patients with moderate to severe chronic obstructive...

2014-04-15 08:29:35

OXFORD, England and PITTSBURGH, April 15, 2014 /PRNewswire/ -- Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, today announced that it has entered into a global licensing agreement with Mylan Inc. (Nasdaq: MYL), one of the world's leading global pharmaceutical companies, for its leading inhaled respiratory products, PSX1001 and PSX1050. PSX1001 and PSX1050, which are the first products to emerge from Prosonix's...


Word of the Day
virgule
  • A punctuation mark (/) used to separate related items of information.
  • A little rod; a twig.
This word comes from the Late Latin 'virgula,' accentual mark, a diminutive of 'virga,' rod.
Related